scholarly journals Pharmacoeconomics of Cancer Therapy

1998 ◽  
Vol 5 (5) ◽  
pp. 415-424 ◽  
Author(s):  
Susan E. Beltz ◽  
Gary C. Yee
Keyword(s):  
Health Care ◽  
Treatment Decision ◽  
Health Care Expenditures ◽  
The United States ◽  
Health Care Environment ◽  
Design Data ◽  
Care Environment ◽  
Treatment Decision Making ◽  
Economic Analyses ◽  
The Cost

Background In 1990, annual costs of the diagnosis and treatment of cancer reached nearly $100 billion and currently constitutes approximately 10% of health care expenditures in the United States. As new and often more expensive therapies for cancer treatment become available, the health care decision- maker must consider the cost effectiveness of the therapy. Methods Key principles of economic analyses and the inherent differences among these analyses are reviewed. Results While pharmacoeconomic analyses are increasingly being used in treatment decision-making, several issues relating to study design, data collection, and research methods are controversial. Conclusions Pharmacoeconomics analyses are necessary in the current health care environment, but the assumptions used within the analyses warrant careful evaluation.

Emerging Innovations: Caring In Action

1999 ◽  
Vol 3 (1) ◽  
pp. 7-11
Author(s):  
Marilyn A. Ray,
Keyword(s):  
Health Care ◽  
International Association ◽  
The United States ◽  
Health Care Environment ◽  
Care Environment ◽  
Universal Health Care System ◽  
The Future ◽  
20Th Anniversary ◽  
Human Caring ◽  
Universal Health

This paper on the future of caring in the challenging health care environment was the end-note address of the 20th anniversary of the International Association for Human Caring held in Philadelphia, Pennsylvania, April, 1998. The focus of the future of caring is on social, transcultural, communal caring, which is a response to the economic corporatization of health care. The need now is for a universal health care system in the United States, to not only care for all citizens, but also to be an example for the rest of the world to heed the call of the Alma-Ata conference of 1978 to provide health care for all early in the new millennium.

No Need for More Regulation: Payors and Their Role in Balancing the Cost and Safety Considerations of Off-Label Prescriptions

2011 ◽  
Vol 37 (2-3) ◽  
pp. 422-443 ◽  
Author(s):  
Amy E. Todd
Keyword(s):  
Health Care ◽  
National Health ◽  
Prescription Drugs ◽  
Health Care Expenditures ◽  
The United States ◽  
Off Label ◽  
Rate Of Growth ◽  
Increased Risk ◽  
Safety Considerations ◽  
The Cost

In 2009, health care expenditures in the United States totaled $2.5 trillion and accounted for almost eighteen percent of the national Gross Domestic Product (GDP). Rising health care costs are an increasing concern in the national health care industry and in government policy reform. When estimates show that thirty percent of health care is unnecessary, improving quality and efficiency of health care could eliminate a significant amount of excessive spending.Prescription drugs contributed to ten percent of national health expenditures in 2009, comprising about $250 billion. And while the rate of growth for overall health care spending declined as a result of the recent recession, “the number of prescription drugs dispensed rebounded to prerecession rate of growth.” Estimates show that off-label drug use comprises between twenty and sixty percent of U.S. prescriptions. This could be a troubling percentage considering that off-label use carries an increased risk of harm or ineffectiveness.

Sign in / Sign up

Export Citation Format

Share Document